{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:50:51Z","timestamp":1790747451959,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific research project of Suining Central Hospital","award":["No. 2022ypj20"],"award-info":[{"award-number":["No. 2022ypj20"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07114-2","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:50:23Z","timestamp":1751431823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Natural history and prognostic nomogram of untreated triple negative breast cancer based on SEER database"],"prefix":"10.1038","volume":"15","author":[{"given":"Dasong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"1","key":"7114_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74(1), 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"7114_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"7114_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/1055-9965.EPI-20-1193","volume":"30","author":"SC Houghton","year":"2021","unstructured":"Houghton, S. C. & Hankinson, S. E. Cancer progress and priorities: Breast cancer. Cancer Epidemiol. Biomark. Prev. 30(5), 822\u2013844 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"7114_CR4","doi-asserted-by":"publisher","first-page":"16036","DOI":"10.1038\/npjbcancer.2016.36","volume":"2","author":"F Pareja","year":"2016","unstructured":"Pareja, F. et al. Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2, 16036 (2016).","journal-title":"NPJ Breast Cancer"},{"key":"7114_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.617593","volume":"10","author":"N Xie","year":"2020","unstructured":"Xie, N. et al. Clinicopathological characteristics and treatment strategies of triple-negative breast cancer patients with a survival longer than 5 years. Front. Oncol. 10, 617593 (2020).","journal-title":"Front. Oncol."},{"key":"7114_CR6","doi-asserted-by":"publisher","first-page":"1119105","DOI":"10.3389\/fendo.2023.1119105","volume":"14","author":"X Meng","year":"2023","unstructured":"Meng, X., Cai, Y., Chang, X. & Guo, Y. A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer. Front. Endocrinol. (Lausanne) 14, 1119105 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"7114_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ 381, e071674 (2023).","journal-title":"BMJ"},{"issue":"5","key":"7114_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1200\/JOP.2017.022632","volume":"13","author":"VK Gadi","year":"2017","unstructured":"Gadi, V. K. & Davidson, N. E. Practical approach to triple-negative breast cancer. J. Oncol. Pract. 13(5), 293\u2013300 (2017).","journal-title":"J. Oncol. Pract."},{"issue":"6","key":"7114_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.2019","volume":"16","author":"X Sun","year":"2024","unstructured":"Sun, X. et al. Nanomaterials for the diagnosis and treatment of triple-negative breast cancer. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 16(6), e2019 (2024).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"11","key":"7114_CR10","doi-asserted-by":"publisher","first-page":"1500053","DOI":"10.1002\/advs.201500053","volume":"2","author":"TF Mendes","year":"2015","unstructured":"Mendes, T. F., Kluskens, L. D. & Rodrigues, L. R. Triple Negative breast cancer: Nanosolutions for a big challenge. Adv. Sci. (Weinh) 2(11), 1500053 (2015).","journal-title":"Adv. Sci. (Weinh)"},{"issue":"2","key":"7114_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s12032-014-0466-x","volume":"32","author":"CM Galmarini","year":"2015","unstructured":"Galmarini, C. M., Tredan, O. & Galmarini, F. C. Survivorship in untreated breast cancer patients. Med. Oncol. 32(2), 466 (2015).","journal-title":"Med. Oncol."},{"issue":"6","key":"7114_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.21037\/atm-22-918","volume":"10","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. The natural history of breast cancer: A chronological analysis of breast cancer progression using data from the SEER database. Ann. Transl. Med. 10(6), 365 (2022).","journal-title":"Ann. Transl. Med."},{"issue":"8","key":"7114_CR13","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/bjc.2013.471","volume":"109","author":"KH Tan","year":"2013","unstructured":"Tan, K. H. et al. Quantifying the natural history of breast cancer. Br. J. Cancer 109(8), 2035\u20132043 (2013).","journal-title":"Br. J. Cancer"},{"issue":"2","key":"7114_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl, S. et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35(2), 159\u2013182 (2024).","journal-title":"Ann. Oncol."},{"key":"7114_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.811878","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Cancer-specific survival outcome in early-stage young breast cancer: Evidence from the SEER database analysis. Front. Endocrinol. (Lausanne) 12, 811878 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"3","key":"7114_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1055-9965.EPI-21-1011","volume":"31","author":"R Strandberg","year":"2022","unstructured":"Strandberg, R., Czene, K., Eriksson, M., Hall, P. & Humphreys, K. Estimating distributions of breast cancer onset and growth in a swedish mammography screening cohort. Cancer Epidemiol. Biomark. Prev. 31(3), 569\u2013577 (2022).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"Suppl 1","key":"7114_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2011-S1-01","volume":"16","author":"CA Hudis","year":"2011","unstructured":"Hudis, C. A. & Gianni, L. Triple-negative breast cancer: An unmet medical need. Oncologist 16(Suppl 1), 1\u201311 (2011).","journal-title":"Oncologist"},{"issue":"1","key":"7114_CR18","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41598-018-38364-y","volume":"9","author":"G Prado-Vazquez","year":"2019","unstructured":"Prado-Vazquez, G. et al. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. Sci. Rep. 9(1), 1538 (2019).","journal-title":"Sci. Rep."},{"issue":"8","key":"7114_CR19","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1097\/JS9.0000000000001586","volume":"110","author":"C Yang","year":"2024","unstructured":"Yang, C. et al. Research hotspots and frontiers of neoadjuvant therapy in triple-negative breast cancer: A bibliometric analysis of publications between 2002 and 2023. Int. J. Surg. 110(8), 4976\u20134992 (2024).","journal-title":"Int. J. Surg."},{"issue":"2","key":"7114_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4143\/crt.2018.342","volume":"51","author":"HK Kim","year":"2019","unstructured":"Kim, H. K. et al. Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast cancer patients: Potential implication of genomic alterations of discordance. Cancer Res. Treat. 51(2), 737\u2013747 (2019).","journal-title":"Cancer Res. Treat."},{"issue":"3","key":"7114_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang, Y. Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies. Cancer Cell 35(3), 428-440.e5 (2019).","journal-title":"Cancer Cell"},{"issue":"4","key":"7114_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdy024","volume":"29","author":"Y Bareche","year":"2018","unstructured":"Bareche, Y. et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann. Oncol. 29(4), 895\u2013902 (2018).","journal-title":"Ann. Oncol."},{"issue":"1","key":"7114_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","volume":"12","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp. Hematol. Oncol. 12(1), 3 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"7114_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1477-7819-10-118","volume":"10","author":"K Joseph","year":"2012","unstructured":"Joseph, K. et al. Outcome analysis of breast cancer patients who declined evidence-based treatment. World J. Surg. Oncol. 10, 118 (2012).","journal-title":"World J. Surg. Oncol."},{"issue":"4","key":"7114_CR25","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1245\/s10434-010-1487-0","volume":"18","author":"E Han","year":"2011","unstructured":"Han, E., Johnson, N., DelaMelena, T., Glissmeyer, M. & Steinbock, K. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann. Surg. Oncol. 18(4), 912\u2013916 (2011).","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"7114_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10238-021-00704-0","volume":"22","author":"M Yao","year":"2022","unstructured":"Yao, M., Wang, S., Chen, L., Wei, B. & Fu, P. Research on correlations of miR-585 expression with progression and prognosis of triple-negative breast cancer. Clin. Exp. Med. 22(2), 201\u2013207 (2022).","journal-title":"Clin. Exp. Med."},{"issue":"6","key":"7114_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6), e0157368 (2016).","journal-title":"PLoS ONE"},{"issue":"5","key":"7114_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41422-023-00795-2","volume":"33","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell Res. 33(5), 389\u2013402 (2023).","journal-title":"Cell Res."},{"key":"7114_CR29","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2147\/CMAR.S185212","volume":"11","author":"N Shao","year":"2019","unstructured":"Shao, N. et al. Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: A surveillance, epidemiology and end results (SEER) analysis. Cancer Manag. Res. 11, 1433\u20131442 (2019).","journal-title":"Cancer Manag. Res."},{"key":"7114_CR30","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.2147\/CMAR.S234926","volume":"11","author":"H Shi","year":"2019","unstructured":"Shi, H., Wang, X. H., Gu, J. W. & Guo, G. L. Development and validation of nomograms for predicting the prognosis of triple-negative breast cancer patients based on 379 Chinese patients. Cancer Manag. Res. 11, 10827\u201310839 (2019).","journal-title":"Cancer Manag. Res."},{"issue":"12","key":"7114_CR31","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.21037\/gs-22-650","volume":"11","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Establishment and verification of a nomogram to predict tumor-specific mortality risk in triple-negative breast cancer: A competing risk model based on the SEER cohort study. Gland Surg. 11(12), 1961\u20131975 (2022).","journal-title":"Gland Surg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07114-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07114-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:50:24Z","timestamp":1751431824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07114-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7114"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07114-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study protocol was approved by the Ethics Committee of Suining Central Hospital. All information from the SEER program is available and free for public, and all patient data are deidentified, so informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"23347"}}